News
A horrifying trip to a new ‘Final Destination,’ collegiate self-reinvention in ‘Overcompensating,’ a new ‘Faust,’ and more.
Rapport Therapeutics, Inc. RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback